At-Home Alzheimer's Injection: What's Coming in 2026

Last August, the FDA approved a weekly subcutaneous maintenance dose of lecanemab (the drug sold as Leqembi), meaning people already on the medication could start self-injecting at home instead of returning to a clinic every two weeks for an IV infusion. That was a real shift in Alzheimer's care, with one catch: patients still had to begin treatment with IV infusions before switching to injections. A second FDA decision, expected May 24, 2026, could change that. If it goes through, an at-home Alzheimer's treatment injection called Leqembi Iqlik would let patients start and stay on treatment without ever sitting in an infusion chair.

What the FDA Is Deciding

Leqembi (lecanemab) is an anti-amyloid antibody therapy approved for early Alzheimer's disease, specifically for people with mild cognitive impairment or early-stage dementia who have confirmed amyloid buildup in the brain. It works by targeting and clearing amyloid plaques, the protein deposits long associated with Alzheimer's progression.

Until recently, treatment required biweekly IV infusions at a hospital or infusion center. That's 26 clinic visits per year. For someone in their 60s or 70s managing early cognitive changes, and for whoever drives them, that schedule is a real burden.

The August 2025 approval addressed the maintenance phase. But getting started still required IV infusions for the initial loading doses. Eisai's January 2026 announcement changed the conversation: the company submitted a supplemental Biologics License Application (sBLA) for Leqembi Iqlik as a subcutaneous starting dose, meaning an autoinjector that handles both the beginning and ongoing maintenance of treatment. The FDA accepted the application under Priority Review and set a PDUFA action date of May 24, 2026.

The proposed starting dose is 500 mg administered via two subcutaneous injections, given once weekly, with no IV needed either to start or to continue.

Why This Matters for Adults 50 and Over

If you or someone you love has been diagnosed with early Alzheimer's, or is being monitored for mild cognitive impairment, this decision has direct, practical implications.

Think about what biweekly IV infusions involve: transportation, scheduling, sitting in a clinical setting for hours, managing potential side effects on-site, and coordinating a care partner's time. Multiply that across months or years of treatment. The Alzheimer's Association has noted that reducing this burden on both patients and care partners is one of the key reasons at-home administration matters, both for convenience and for making long-term treatment sustainable.

Alzheimer's disease affects an estimated 6.9 million Americans age 65 and older, according to the Alzheimer's Association's 2024 Facts and Figures report. Early intervention, the window where Leqembi is indicated, is exactly the phase where treatment accessibility can shape outcomes. If the barrier to starting is a rigid infusion schedule, some people won't start, and some who do will stop.

An autoinjector changes that math by putting more control in the hands of patients and the people who care for them at home.

What the Evidence Shows

The clinical case for lecanemab has been building for several years, and the long-term data is now strong enough to take seriously. The pivotal Clarity AD trial showed that lecanemab slowed clinical decline by 27% over 18 months compared to placebo, a meaningful number in a disease where any slowing matters.

More recently, a 2025 peer-reviewed study published in PMC reported 36-month results from the Clarity AD Open-Label Extension (OLE) study. The findings are worth reading carefully. Patients who continued on lecanemab showed sustained clinical and quality-of-life benefits out to three years. ARIA (amyloid-related imaging abnormalities, the primary safety concern with this class of drugs) occurred mostly in the first six months of treatment, after which rates dropped to levels seen in the placebo group. No new safety signals emerged over the extended follow-up period.

That ARIA timeline is relevant to the subcutaneous formulation conversation. The highest-risk window appears to be early treatment, and it's already been the focus of monitoring protocols. The long-term data suggests that patients who get through the initial phase without serious complications tend to tolerate continued treatment well.

Lecanemab isn't for everyone. It's indicated for early-stage disease, requires diagnostic confirmation of amyloid pathology (typically via PET scan or cerebrospinal fluid test), and is not appropriate for people on blood thinners or those with certain genetic profiles. A neurologist experienced in Alzheimer's care is the right person to assess eligibility.

What Happens After May 24, 2026

Three things could happen. The FDA approves Leqembi Iqlik as a starting dose: full approval, potentially with labeling conditions. It approves with modifications or requests additional data. Or it doesn't approve, at least not yet.

Priority Review designation doesn't guarantee approval; it means the FDA committed to reviewing the application within six months rather than the standard twelve. The designation is granted when a drug has the potential to provide a significant improvement in safety or effectiveness for a serious condition. Getting that designation is meaningful, but it isn't a rubber stamp.

If approved, the practical rollout would depend on insurance coverage, prescriber training, and pharmacy distribution, none of which happen overnight. Medicare coverage for lecanemab has been a complicated and evolving story. Costs and access will vary. But the regulatory green light would be the essential first step.

Video: Alzheimer's drug lecanemab granted full approval by FDA, Mayo Clinic expert weighs in (Mayo Clinic)

What You Can Do Right Now

You don't need to wait for May 24 to take useful steps. These are things you can do today.

If you or a family member has been diagnosed with early Alzheimer's or MCI: Ask your neurologist specifically about lecanemab eligibility and what the amyloid confirmation process looks like at your care center. Ask about the current subcutaneous maintenance option if IV infusions are a barrier. Start the conversation before access changes again.

If you're in the monitoring phase: Know your cognitive baseline. Routine assessments, documented over time, give clinicians, and you, a clearer picture of whether and how much is changing. This is the kind of data that informs treatment decisions.

Think about lifestyle factors that support brain health: The evidence for certain lifestyle interventions is real and consistent. Regular physical activity, quality sleep, social connection, and a diet that keeps blood sugar and inflammation in check all show up in the research as protective factors. Hydration matters more than most people realize; even mild chronic dehydration affects cognitive function. SteadiDay's food and water tracking, part of Premium, makes it easy to track both nutrition and fluid intake daily, which is a simple place to start if you haven't been paying attention to either.

Follow the FDA decision directly: The May 24, 2026 date is a PDUFA date: a commitment by the FDA to take action by that date. FDA.gov updates drug approval decisions in real time. You can also follow Eisai's news releases and the Alzheimer's Association's treatment updates page for plain-language summaries as they happen.

The Bigger Picture

Alzheimer's drug development has had more failures than any field in medicine wants to count. Lecanemab is one of a small number of therapies that has cleared the clinical bar for disease modification rather than symptom management alone, and that distinction matters.

The move toward an at-home Alzheimer's treatment injection is a convenience upgrade, and it also reflects a broader shift in how the medical system is starting to think about chronic disease management: treatment should fit into people's lives, not the other way around. For older adults managing early cognitive changes, who want to stay in their homes, maintain their routines, and hold on to as much independence as possible for as long as possible, that principle has very practical consequences.

That is why the May 24 decision is worth watching.